Agios Pharmaceuticals, Inc. (AGIO) Stake Increased by Pictet Asset Management Ltd.

Pictet Asset Management Ltd. lifted its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 198.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 54,700 shares of the biopharmaceutical company’s stock after buying an additional 36,400 shares during the period. Pictet Asset Management Ltd. owned approximately 0.11% of Agios Pharmaceuticals worth $3,651,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in AGIO. Creative Planning increased its holdings in Agios Pharmaceuticals by 1.4% in the 2nd quarter. Creative Planning now owns 16,710 shares of the biopharmaceutical company’s stock valued at $860,000 after purchasing an additional 228 shares during the last quarter. Public Employees Retirement Association of Colorado boosted its position in Agios Pharmaceuticals by 5.2% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 6,504 shares of the biopharmaceutical company’s stock valued at $335,000 after buying an additional 323 shares during the period. BNP Paribas Arbitrage SA boosted its position in Agios Pharmaceuticals by 2.9% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 13,575 shares of the biopharmaceutical company’s stock valued at $698,000 after buying an additional 385 shares during the period. Janney Montgomery Scott LLC boosted its position in Agios Pharmaceuticals by 9.7% in the 2nd quarter. Janney Montgomery Scott LLC now owns 4,820 shares of the biopharmaceutical company’s stock valued at $248,000 after buying an additional 425 shares during the period. Finally, Teachers Advisors LLC boosted its position in Agios Pharmaceuticals by 2.3% in the 1st quarter. Teachers Advisors LLC now owns 30,258 shares of the biopharmaceutical company’s stock valued at $1,767,000 after buying an additional 666 shares during the period. Institutional investors and hedge funds own 93.16% of the company’s stock.

In other Agios Pharmaceuticals news, Director Lewis Clayton Jr. Cantley sold 4,000 shares of the company’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $56.85, for a total value of $227,400.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Scott Biller sold 2,146 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $61.99, for a total transaction of $133,030.54. Following the completion of the sale, the insider now directly owns 8,410 shares in the company, valued at approximately $521,335.90. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 178,908 shares of company stock worth $12,147,719. Company insiders own 10.55% of the company’s stock.

WARNING: “Agios Pharmaceuticals, Inc. (AGIO) Stake Increased by Pictet Asset Management Ltd.” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://ledgergazette.com/2017/11/13/agios-pharmaceuticals-inc-agio-stake-increased-by-pictet-asset-management-ltd.html.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) opened at $62.05 on Monday. Agios Pharmaceuticals, Inc. has a one year low of $39.24 and a one year high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.78) by $0.19. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The business had revenue of $11.35 million for the quarter, compared to analyst estimates of $10.85 million. During the same period in the previous year, the business posted ($1.63) earnings per share. The business’s revenue was up 26.4% compared to the same quarter last year. sell-side analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.59 earnings per share for the current year.

Several brokerages have commented on AGIO. BidaskClub cut shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. SunTrust Banks, Inc. reissued a “buy” rating and issued a $80.00 price target (up previously from $68.00) on shares of Agios Pharmaceuticals in a research report on Tuesday, August 8th. Needham & Company LLC lifted their price objective on shares of Agios Pharmaceuticals from $54.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, August 10th. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $83.00 price objective (up from $75.00) on shares of Agios Pharmaceuticals in a research report on Thursday, August 10th. Finally, Leerink Swann raised shares of Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $50.00 to $80.00 in a research report on Wednesday, August 2nd. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Agios Pharmaceuticals has an average rating of “Buy” and an average target price of $75.70.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply